Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
Status:
Not yet recruiting
Trial end date:
2023-09-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to further evaluate the long-term safety and tolerability of
daily dosing of rimegepant for the prevention of episodic migraine.